Almac Diagnostic Services, part of the Almac Group, today announces further investment in its global Next Generation Sequencing (NGS) infrastructure to support biomarker driven clinical research.
This infrastructure expansion includes the addition of Thermo Fisher Scientific’s Ion Torrent Genexus™ System, which supports the delivery of high‑quality genomic data for biomarker discovery and patient stratification in both early- and late-phase clinical trials. It also strengthens Almac’s targeted DNA and RNA sequencing offerings, reinforcing its position as a trusted partner for precision medicine.
Sponsors will now benefit from an integrated, end‑to‑end NGS workflow made possible by the Ion Torrent Genexus™ System, which combines library preparation, sequencing, data analysis and reporting within a single platform. Automation of key steps reduces manual handling and variability, helping to deliver consistent, high‑quality genomic data with faster turnaround times.
By expanding NGS capabilities within its laboratory, Almac Diagnostic Services further strengthens its ability to support global clinical trials from its existing multi-omic laboratories in UK / Europe and the United States. This latest investment reflects its ongoing commitment to expand its clinical trial solutions, supporting biopharmaceutical partners evolving needs for global technologies that enable biomarker‑driven, drug development programmes.
Michael Sloan, Global Vice President of Commercial Operations, Almac Diagnostic Services, commented:
“This investment further enhances our NGS capabilities for biopharma partners. The platform supports faster, more streamlined genomic testing while maintaining the quality, consistency and regulatory rigour required for clinical trial applications.
It forms part of our ongoing strategy to invest in technologies that help customers accelerate development and bring targeted therapies to patients sooner.”
For more information on Almac Diagnostic Services range of services visit: www.almacgroup.com/diagnostics
About Almac Diagnostic Services
Almac Diagnostic Services is a precision medicine company, specialising in biomarker‑driven clinical trials. The company supports global pharmaceutical and biotechnology customers with biomarker strategies from discovery through to companion diagnostic partnerships. Almac operates clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling global study support.
Core services include:
- Multi-Omic Services
- Clinical Biomarker & Companion Diagnostic Development
- Clinical Trial Testing
For more information, visit www.almacgroup.com/diagnostics.
About Almac Group
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture and supply.
Almac is a privately owned organisation which has grown organically, now employing more than 7,900 highly skilled personnel across 18 facilities including Europe, the USA and Asia.
To keep up to date with the latest news, follow us on X and LinkedIn or visit almacgroup.com.
